Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, describes her level of comfort with using biosimilars in practice.
Transcript:
Are you comfortable with using a biosimilar for your patient?
I’m comfortable in starting my patient on a biosimilar versus its originator, assuming that it works equally well, that there are no glitches in access, and that the federal government has inspected the makers of that biosimilar as much as they inspect the originators, because I know there is a whole process of compliance and specifications that needs to happen.
I worry that they’re able to do that if they’re made in India or Korea or wherever. I’m not so worried about the biosimilars that are made in this country by the companies that are already making them in this country, because we know there are differences, so I would want to see very careful inspection of the company or manufacturing plants that are making them.
So, let’s assume all of that is the case and the process of accessing the biosimilar is equal to the process of accessing the originator, so you don’t end up with short falls—the needle works as well, the boxes are similar, all of the practical considerations—I think it would be fine.
What I do not want to see is people being forced off of their drug that works, or multiple switching. Even worse, I don’t want to see multiple switching where I’m not told or the patient is not told. For that matter, I don’t want to see [any] switches [at all] where I’m not told or the patient isn’t told.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.